EU watchdog looking into impact on drug availability from Catalent-Novo deal
FRANKFURT (Reuters) -The European Union's drugs regulator said on Wednesday it will investigate any risks to the availability of medicines processed at Catalent sites that will be sold to Novo Nordisk, part of its mandate to prevent drug shortages. The European Medicines Agency told Reuters in a statement that its Medicine Shortages Single Point of Contact (SPOC) Working Party will liaise with member states to gather data on the products manufactured at the sites. Novo Nordisk on Monday moved to boost output of its popular obesity drug Wegovy as its parent holding struck a deal to buy C...